(Reuters) - British medical property owner REIT Assura (AGR.L) has agreed to a 1.61 billion pound ($2.06 billion) takeover bid from KKR (KKR) and Stonepeak Partners, after rejecting a lower cash-and-stock proposal from peer Primary Health Properties (PHP.L). Assura joins a growing list of UK companies bought out and taken private by overseas private equity firms or investment companies, attracted by cheap valuations. KKR and Stonepeak understand that Assura's capital-intensive strategy can be more effectively supported through private ownership, enabling sustained capital investments without the need for asset sales, the statement said. The U.S.-based private equity firms have offered to buy Assura for 49.4 pence-per-share. The bid was the fifth involving KKR and is at a 33.5% premium to the closing price on February 13, a day before the first bid was disclosed. Under the terms of the deal, shareholders will get 48.56 pence in cash for each share held and a quarterly interim dividend of 0.84 pence that was due to be paid on April 9. Assura, which counts the National Health Service among its clients, said it intends to recommend that the shareholders vote in favour of the deal. "The cash offer from KKR and Stonepeak offers an attractive opportunity for Assura shareholders to crystallise value immediately," CEO Jonathan Murphy said. Earlier on Wednesday, Assura rejected peer PHP's proposal. At 46.2 pence per share, it was lower than the KKR-Stonepeak proposal, although it included an option to "mix and match" varying proportions of shares and cash. PHP, which has until May 5 to make a firm offer, declined to comment. Assura's shares rose as much as 5.6% to 47.7 pence in early trade on Wednesday and have surged about 29% since the start of the offer period. ($1 = 0.7799 pounds) (Reporting by Aby Jose Koilparambil, Raechel Thankam Job and Chandini Monnappa in Bengaluru; Editing by Nivedita Bhattacharjee, Mrigank Dhaniwala and Barbara Lewis)
UK's Assura agrees to $2.06 billion takeover by KKR-Stonepeak
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...